Compare APYX & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APYX | ACRV |
|---|---|---|
| Founded | 1982 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.0M | 82.7M |
| IPO Year | 1987 | 2022 |
| Metric | APYX | ACRV |
|---|---|---|
| Price | $3.86 | $2.53 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $8.00 | ★ $14.67 |
| AVG Volume (30 Days) | 120.7K | ★ 531.6K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $47,902,000.00 | N/A |
| Revenue This Year | $8.50 | N/A |
| Revenue Next Year | $7.18 | $805.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.76 | $1.05 |
| 52 Week High | $4.44 | $8.00 |
| Indicator | APYX | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 51.41 | 59.17 |
| Support Level | $3.92 | $2.44 |
| Resistance Level | $4.14 | $2.73 |
| Average True Range (ATR) | 0.19 | 0.17 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 15.22 | 64.91 |
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment derives the majority of its revenue.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.